John B. Moriarty, Jr. net worth and biography

John Moriarty, Jr. Biography and Net Worth

Chief Legal Officer and Corporate Secretary of Avidity Biosciences

John B. Moriarty, Jr., J.D. has served as our Chief Legal Officer and Corporate Secretary since August 2024 and brings significant global legal and business leadership expertise to Avidity as a strategic advisor to Boards of Directors and executive management.

He has successfully scaled numerous global biotech companies and most recently served as Executive Vice President and Chief Legal Officer of Mirati Therapeutics through its 2024 acquisition by Bristol-Myers Squibb, Chief Legal Officer of Olema Oncology through its 2020 initial public offering, Executive Vice President and General Counsel of Portola Pharmaceuticals through its 2020 acquisition by Alexion Pharmaceuticals, and Executive Vice President and General Counsel of Alexion Pharmaceuticals as it grew to an S&P 500 global company and where he also directed the company’s global government and corporate affairs teams. Mr. Moriarty previously was Senior Vice President and General Counsel of Elan Pharmaceuticals and earlier in his career was a healthcare fraud prosecutor with the U.S. Attorney’s Office, in private practice with a national law firm, and Associate General Counsel at Amgen.

Mr. Moriarty received a B.A. from the University of Virginia and a J.D. cum laude from the University of Georgia School of Law.

What is John B. Moriarty, Jr.'s net worth?: The estimated net worth of John B. Moriarty, Jr. is at least $3.42 million as of August 4th, 2025. Mr. Moriarty, Jr. owns 47,755 shares of Avidity Biosciences stock worth more than $3,416,393 as of December 5th. This net worth estimate does not reflect any other investments that Mr. Moriarty, Jr. may own. Learn More about John B. Moriarty, Jr.'s net worth.
How do I contact John B. Moriarty, Jr.?: The corporate mailing address for Mr. Moriarty, Jr. and other Avidity Biosciences executives is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. Avidity Biosciences can also be reached via phone at 858-401-7900 and via email at [email protected]. Learn More on John B. Moriarty, Jr.'s contact information.
Has John B. Moriarty, Jr. been buying or selling shares of Avidity Biosciences?: John B. Moriarty, Jr. has not been actively trading shares of Avidity Biosciences during the last quarter. Most recently, John B. Moriarty sold 2,245 shares of the business's stock in a transaction on Monday, August 4th. The shares were sold at an average price of $36.21, for a transaction totalling $81,291.45. Following the completion of the sale, the insider now directly owns 47,755 shares of the company's stock, valued at $1,729,208.55. Learn More on John B. Moriarty, Jr.'s trading history.
Who are Avidity Biosciences' active insiders?: Avidity Biosciences' insider roster includes Sarah Boyce (President & CEO), W. Flanagan (Insider), Kathleen Gallagher (Insider), Steven Hughes (Insider), Arthur Levin (Insider), Michael MacLean (Chief Financial and Chief Business Officer), Teresa Mccarthy (Insider), John Moriarty, Jr. (Chief Legal Officer and Corporate Secretary), Eric Mosbrooker (Chief Commercial Officer), Tamar Thompson (Director), and Troy Wilson (Director). Learn More on Avidity Biosciences' active insiders.
Are insiders buying or selling shares of Avidity Biosciences?: During the last year, insiders at the biotechnology company sold shares 35 times. They sold a total of 788,205 shares worth more than $33,292,671.98. The most recent insider tranaction occured on October, 22nd when insider Steven George Hughes sold 2,209 shares worth more than $105,015.86. Insiders at Avidity Biosciences own 3.8% of the company. Learn More about insider trades at Avidity Biosciences.
Information on this page was last updated on 10/22/2025.

John B. Moriarty, Jr. Insider Trading History at Avidity Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/4/2025	Sell	2,245	$36.21	$81,291.45	47,755

John B. Moriarty, Jr. Buying and Selling Activity at Avidity Biosciences

Avidity Biosciences Company Overview

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Today's Range

Now: $71.54

$71.42

$71.69

50 Day Range

MA: $60.79

$42.63

$71.58

2 Week Range

Now: $71.54

$21.51

$71.78

Volume

2,514,106 shs

Average Volume

2,988,567 shs

Market Capitalization

$10.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.9